Transcode Therapeutics (RNAZ) EPS (Basic) (2020 - 2026)
Transcode Therapeutics' (RNAZ) quarterly EPS (Basic) came in at -$21.28 in Q1 2026, up 69.68% YoY from -$12.54 in Q1 2025, and up 2.51% on a QoQ basis from -$21.83 in Q4 2025.
Transcode Therapeutics (RNAZ) EPS (Basic) (2020 - 2026) Analysis & Trends
Transcode Therapeutics (RNAZ) has 7 years of EPS (Basic) data on file, last reported at -$21.28 in Q1 2026.
- Quarterly EPS (Basic) rose 69.68% year-over-year to -$21.28 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$47.65 (up 67.87% YoY) and the FY2025 annual result came in at -$52.59, up 96.02% from the prior year.
- EPS (Basic) climbed to -$21.28 in Q1 2026, from -$21.83 in the prior quarter.
- In the past five years, EPS (Basic) ranged from a high of -$5.13 in Q2 2025 to a low of -$319222.4 in Q2 2022.
- A 5-year average of -$96049.2 and a median of -$680.41 in 2024 frame the typical range for EPS (Basic).
- Annual changes were most pronounced in 2022 — EPS (Basic) plunged 169.12% — and 2024, when it soared 99.77%.
- Tracing RNAZ's EPS (Basic) over 5 years: stood at -$305684.9 in 2022, then jumped by 93.07% to -$21184.4 in 2023, then soared by 97.79% to -$467.61 in 2024, then surged by 95.33% to -$21.83 in 2025, then gained by 2.51% to -$21.28 in 2026.
- The last three EPS (Basic) figures came in at -$21.28 (Q1 2026), -$21.83 (Q4 2025), and -$5.82 (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Basic) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 4.34 |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 12.62 |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 7.59 |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -1.96 |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 2.12 |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 1.23 |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -0.72 |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -0.06 |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 0.18 |
| 10 | Transcode Therapeutics | 2.84 Mn | 2.84 Mn | - | -7.17 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.28 |
| Dec 31, 2025 | -21.83 |
| Sep 30, 2025 | -5.82 |
| Jun 30, 2025 | -5.13 |
| Mar 31, 2025 | -70.17 |
| Dec 31, 2024 | -467.61 |
| Sep 30, 2024 | -146.10 |
| Jun 30, 2024 | -680.41 |
| Mar 31, 2024 | -597.92 |
| Dec 31, 2023 | -21,184.42 |
| Sep 30, 2023 | -64,478.86 |
| Jun 30, 2023 | -147,545.92 |
| Mar 31, 2023 | -263,676.74 |
| Dec 31, 2022 | -305,684.94 |
| Sep 30, 2022 | -313,610.83 |
| Jun 30, 2022 | -319,222.39 |
| Mar 31, 2022 | -195,416.06 |
| Dec 31, 2021 | -264,411.27 |
| Sep 30, 2021 | -446,637.63 |
| Jun 30, 2021 | 461,817.33 |